Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | Distinguishing between de novo AML and secondary AML using mutational signatures

Peter Valk • 29 Sep 2022
SOHO 2022
Acute Myeloid Leukemia Leukemia

Peter Valk, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, shares some insights into the importance of distinguishing between de novo acute myeloid leukemia (AML) and secondary AML using specific mutational signatures, and how this can be carried out in clinical practice. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Peter Valk

1:03
Future considerations for MRD in AML
Peter Valk • 29 Sep 2022
3:22
Is TP53-mutated high-risk MDS the same disease as TP53-mutated AML?
Peter Valk • 29 Sep 2022
1:49
The prognostic value of FLT3-ITD residual disease in AML
Peter Valk • 29 Sep 2022
2:44
Ongoing and future AML research at the Valk Lab
Peter Valk • 1 Apr 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals